CervoMed (NASDAQ:CRVO) and BeOne Medicines (NASDAQ:ONC) Financial Survey

BeOne Medicines (NASDAQ:ONC) and CervoMed (NASDAQ:CRVO) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Analyst Recommendations

This is a summary of current recommendations for BeOne Medicines and CervoMed, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	0	2	13	2	3.00
CervoMed	1	1	4	1	2.71

BeOne Medicines presently has a consensus price target of $407.07, indicating a potential upside of 7.80%. CervoMed has a consensus price target of $21.00, indicating a potential upside of 809.09%. Given CervoMed’s higher probable upside, analysts clearly believe CervoMed is more favorable than BeOne Medicines.

Volatility & Risk

BeOne Medicines has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, CervoMed has a beta of -0.75, indicating that its share price is 175% less volatile than the S&P 500.

Profitability

This table compares BeOne Medicines and CervoMed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	10.70%	14.23%	7.82%
CervoMed	N/A	-156.02%	-128.34%

Insider & Institutional Ownership

48.5% of BeOne Medicines shares are held by institutional investors. Comparatively, 25.2% of CervoMed shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Comparatively, 35.8% of CervoMed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares BeOne Medicines and CervoMed”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34 billion	7.76	$286.93 million	$5.68	66.48
CervoMed	$4.01 million	8.71	-$26.97 million	($3.22)	-0.72

BeOne Medicines has higher revenue and earnings than CervoMed. CervoMed is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Summary

BeOne Medicines beats CervoMed on 11 of the 14 factors compared between the two stocks.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

About CervoMed

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.